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The S100 family of proteins consists of at least 13 EF-hand
containing proteins which exhibit a cell type-specific distribution
in normal cells (Schäfer and Heizmann, 1996). Five of these
proteins, S100A2–S100A6 are clustered within 18 kbp of one
another on chromosome 1 of the human genome (Pedrocchi et al,
1994). Although the functions of these S100 proteins are not
known with any certainty (Donato, 1999), for some, their altered
expression has been associated with cancer cells. For example,
high S100A6 levels in melanomas is associated with decreased
survival of patients (Maelandsmo et al, 1997). Elevated levels of
S100A4 are strongly associated with the ability of tumour cells to
metastasize in cell and transgenic mouse models of breast cancer
(Davies et al, 1993, 1996; Ambartsumian et al, 1996), and further-
more, immunocytochemically detected S100A4 in the tumours
from an archival group of 349 breast cancer patients has recently
been shown to be associated with early patient death (Platt-
Higgins et al, 2000; Rudland et al, 2000). However, in contrast to
the up-regulation of these two S100 proteins in cancer cells, the
mRNA for S100A2 has been reported to be abundant in cells
cultured from normal human breast, but to be absent in breast
carcinoma-derived cells (Lee et al, 1992). The loss of expression
of S100A2 in cancer cell lines relative to normal breast-derived
cells has been linked to increased methylation of the S100A2 gene
in the cancer cells (Lee et al, 1992; Wicki et al, 1997). However, a
tumour biopsy sample subjected to genomic sequencing suggested
that not all cells contained methylated DNA in the promoter region
of the S100A2 gene, probably reflecting heterogeneity of the spec-
imen (Wicki et al, 1997). Using transactivation assays, it has been
shown that the S100A2 promoter can be transcriptionally activated
by wild-type, but not by mutant p53 (Tan et al, 1999).
As part of a programme of identifying genes that are differen-
tially expressed between human benign and malignant breast 
cell lines using suppression subtractive hybridization, we recently
identified S100A2 mRNA as one that was present at a higher level
in the benign relative to the malignant cells, suggesting that
S100A2 is produced in benign tumour cells. Thus, using in situ
hybridization, the distribution of S100A2 mRNA has been sought
in benign breast lesions, carcinomas in situ and carcinoma
specimens. The results have been related to the p53 status of the
specimens.
MATERIALS AND METHODS
Human breast tissue and cell lines
Human breast specimens were obtained from the CANDIS Cancer
Tissue Bank Research Centre and the Royal Liverpool University
Hospital (Liverpool, UK) as described previously (Anandappa et
al, 1994; Taylor et al, 1997). Characteristics of the specimens are
shown in Table 1. Immunocytochemical detection of p53 was
carried out as described previously (Platt-Higgins et al, 2000).
The normal human mammary epithelial cell line, Huma 7,
subcloned from primary cultures derived from reduction mam-
moplasty specimens of normal breast tissue which had been
immortalized with SV40 virus (Rudland et al, 1989), the benign
human mammary epithelial cell line, Huma 123, and the derivative
benign human mammary myoepithelial-like cell line, Huma 
109 (Ke et al, 1993), derived from HMT-3522 which was 
itself derived from a primary cell culture of human fibrocystic
disease displaying prominent epithelial hyperplasia (Briand 
et al, 1987), the malignant human mammary epithelial cell lines
derived from pleural effusions of breast cancer patients, MCF-7A,
T-47D, ZR-75 and MDA-MB-231 (Engel and Young, 1978) were
cultured as described previously (Rudland et al, 1989; Ke et al,
1993).
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Subtractive hybridization
A suppression subtracted (Diatchenko et al, 1996) library con-
sisting of polymerase chain reaction (PCR) products representing
mRNAs expressed at a higher level in the benign human breast-
derived cell line, Huma 123, relative to the malignant breast
epithelial cell line MCF-7A was constructed using a PCR-Select™
cDNA Subtraction Kit (Clontech, Palo Alto, California, USA),
according to the manufacturer’s methodology.
A blunt-ended vector was prepared from pBluescript KS 
(Stratagene, La Jolla, USA) which was digested to completion
with  EcoRV (Roche Molecular Biochemicals, Mannheim,
Germany). The digested plasmid DNA was purified by phenol/
chloroform extraction and ethanol precipitation (Sambrook et al,
1989). The linear, blunt-ended plasmid DNA was tailed with
10 µ M dideoxythymidine triphosphate (ddTTP) (Pharmacia,
Uppsala, Sweden) using 100 units of terminal transferase (Roche
Molecular Biochemicals, Mannheim, Germany) in the buffer
supplied by the manufacturer at 37˚C for 1.5 h. The ddT-tailed
vector was purified by phenol/chloroform extraction, followed
by ethanol precipitation.
PCR products constituting the subtracted library were ligated
into the ddT-tailed pBluescript vector using T4 DNA ligase (New
England Biolabs, Hertfordshire, UK) in the buffer supplied by the
manufacturer and incubated at 5–8˚C overnight. E. coli cells XL-1
Blue (Stratagene, La Jolla, USA) were transformed by electro-
poration (2.5 kV, 25 µ FD, 200  , time constant 4–5) using a Gene
Pulser unit (Bio-Rad laboratories, Hertfordshire, UK), and plated
onto agar plates containing 100 µ g ml–1 ampicillin, and 40 µ M
isopropyl-β -D-thiogalactopyranoside (IPTG), 32 µ g ml–1  5-
bromo-4-chloro-3-indolyl-β -D-galactoside (X-gal) for blue/white
colour selection. Randomly picked individual positive colonies
from the selection plates were grown overnight in LB medium
containing 100 µ g ml–1 ampicillin in 96-well plates at 37˚C and
their plasmid DNA analysed by reverse Northern blotting to
confirm the differential expression of the picked clones.
Reverse Northern screening of the subtracted cDNA
libraries
One µ l of each culture was amplified by PCR in 20 µ l reactions
using the Advantage KlenTaq Polymerase Mix (Clontech, Palo
Alto, California, USA). More than 98% of the randomly picked
clones contained inserts. After amplification, PCR products were
subjected to agarose gel electrophoresis and the amount of DNA
determined from the intensity of the ethidium bromide-stained
bands. Equal amounts of PCR products were combined with a
measured amount of bromophenol blue dye solution, denatured
and blotted onto duplicate Nylon membranes (Amersham, Bucks,
UK) using a 48-well slot-blot apparatus (Anachem-Scotlab, Luton,
UK). Filters were checked that each slot contained the same
intensity of dye. The filters were hybridized (Sambrook et al,
1989) with equivalent amounts of double-stranded cDNA derived
from driver (MCF-7A) and tester (Huma 123) mRNA respectively
which had been labelled to approximately equal specific activity
(1 × 109 d.p.m.µ g–1 DNA) with [α 32P] dCTP (ICN, Hampshire,
UK). After being washed twice for 15 min each at room tempera-
ture with 2 × SSPE (1 × SSPE = 180 mM NaCl, 10 mM sodium
phosphate, 1 mM EDTA, pH 7.4), 0.1% (w/v) sodium dodecyl
sulphate (SDS), twice for 15 min each at 68˚C with 1 × SSPE,
0.1% (w/v) SDS, and twice for 20 min each at 68˚C with
0.1 × SSPE, 0.1% (w/v) SDS, filters were exposed to X-ray film
(Kodak X-AR 5) with an intensifying screen at  80˚C overnight.
The resultant autoradiographic images were analysed using
IMAGE software (NIH, Bethesda, USA) on a Macintosh
computer.
Northern blotting
Total cellular RNA was prepared using the guanidinium-
isothiocyanate-caesium chloride method (Chirgwin et al, 1979;
Barraclough et al, 1987; Han et al, 1987). Poly(A)-containing
RNA was isolated from total RNA using the Fast Track mRNA
isolation kit (Invitrogen, Groningen, Netherlands). Gel electro-
phoresis of 10 µ g aliquots of total RNA in formaldehyde
and Northern blotting was performed as described previously
(Sambrook et al, 1989), and filters were washed as for reverse
Northern hybridization. The S100A2 cDNA probe was the same as
the 258 bp probe used for in situ hybridization (see below) and
was labelled by random-primed DNA synthesis (Feinberg
and Vogelstein, 1984) using a labelling kit (Roche Molecular
Biochemicals, Mannheim, Germany) to 1 × 109 d.p.m.µ g–1 DNA.
The constitutive probe, 36B4, a cDNA to human acidic ribosomal
phosphoprotein PO mRNA (Laborda, 1991), was used to normal-
ize RNA loading.
In situ hybridization
Paraffin-embedded, 5-µ m human breast tissue sections corres-
ponding to normal tissue and tumour specimens were subjected to
RNA in situ hybridization. A 258-bp fragment of human S100A2
cDNA obtained from the Huma 123 subtracted library (bases
103 to 360 inclusive of GenBank accession number M87068),
cloned into pBluescript KS  was used as a template to generate
Digoxigenin (DIG)-labelled sense and antisense cRNA by in vitro
transcription from the flanking T7 and T3 RNA polymerase
promoter sites in the pBluescript vector using a DIG-labelling
system (Roche Molecular Biochemicals, Mannheim, Germany)
according to the manufacturer’s methods. The yields of 
DIG-labelled cRNA were estimated by spotting diluted aliquots 
of the labelled cRNA onto filters and analysing them with a 
DIG-labelled control RNA using a nitro-blue tetrazolium
(NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) colorimetric
DIG-detection system (Roche Molecular Biochemicals, Mannheim,
Germany). One µ g of linearized plasmid DNA template 
normally generated about 10 µ g of DIG-labelled cRNA probe
which was stored as aliquots at  80˚C without observable
degradation.
Table 1 Characteristics of tumour specimens
Total number of normal specimens 8
Of which from normal breast 3
Of which from specimens with no residual carcinoma 5
Total number of benign specimensa 15
Of which p53 positive 2
Of which p53 negative 11
Of which of unknown p53 status 2
Total number of carcinoma specimens 27
Of which invasive ductal carcinoma and DCIS 19
Of which p53 positive 12
Of which p53 negative 11
Of which of unknown p53 status 4
aBenign specimens consisted of 7 fibroadenomas and 8 fibrocystic diseases,
which included hyperplasias of usual type.The tissue sections were de-waxed in fresh xylene, rehydrated
with a graded series of ethanol solutions, washed once with 1 ×
phosphate-buffered saline (PBS) buffer (140 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH 7.4) and post-
fixed with diethyl pyrocarbonate (DEPC)-treated PBS containing
4% (w/v) paraformaldehyde (MERCK, Dorset, UK) for 30 min
at 4˚C to preserve the mRNA. The sections were treated with
200 mM HCl to denature the protein, and the tissue was acetylated
in 0.5% (v/v) acetic anhydride (Sigma, St. Louis, USA) in
100 mM Tris-HCl pH 8.0 to reduce non-specific background. The
sections were incubated with 20 µ g ml–1 RNase-free Proteinase K
(Roche Molecular Biochemicals, Mannheim, Germany) in 50 mM
Tris-HCl, pH 7.6, buffer containing 150 mM NaCl and 2 mM
CaCl2 for 30 min at 37˚C. After being washed with PBS, the
sections were dehydrated in a series of ethanol solutions and the
slides rinsed briefly with chloroform. After prehybridization in a
solution of 5 × SSPE, 50% (v/v) deionized formamide and 5 ×
Denhardt’s reagent at 42˚C for 1 h, each section was incubated
with 200 µ l or 500 µ l (depending on the size of the section) of
prehybridization buffer containing 5 mM dithiothreitol, 5% (w/v)
dextran sulphate, 100 µ g ml–1 sheared, denatured salmon sperm
DNA, and 200 ng ml–1 of DIG-labelled antisense or sense cRNA
for 16–18 h at 42˚C. After being washed at room temperature for
15 min with 2 × SSC (1 × SSC = 150 mM NaCl, 15 mM sodium
citrate, pH 7.0), for 15 min with 1 × SSC, and for 30 min at 50˚C
with 0.2 × SSC and 50% (v/v) deionized formamide, the slides
were washed at room temperature for 15 min with 0.1 × SSC.
Colour was developed using anti-Digoxigenin Fab fragments
(from sheep), conjugated to alkaline phosphatase and the
NBT/BCIP colorimeric detection system (Roche Molecular
Biochemicals, Mannheim, Germany), according to the manufac-
turer’s recommendations. The stained sections were examined by
two independent observers, and the results were expressed as for
immunocytochemistry above.
Reverse transcription multiplex PCR analysis for
S100A2 and glyceraldehyde 3-phosphate
dehydrogenase cDNAs
Two µ g of total RNA was reverse transcribed in a final volume
of 10  µ l with 200 units of SuperScriptTM RNase H– Reverse
Transcriptase (Life Technologies Ltd, Paisley, UK), and subse-
quently 1 µ l of this first strand cDNA reaction mixture was ampli-
fied by PCR with Taq DNA Polymerase (Life Technologies Ltd,
Paisley, UK). For S100A2 cDNA the forward primer (5’ position at
base 103, of GenBank accession number M87068) was 5’-CCAA-
GAGGGCGACAAGTTCAAG-3’ and the reverse primer (5’ posi-
tion at base 339) was 5’-CATGGCAGGGAGTCAAGAGTTC-3’.
For the human glyceraldehyde 3-phosphate dehydrogenase cDNA
the forward, 5’-ACCACAGTCCATGCCATCAC-3’ and reverse
primer, 5’-TCCACCACCCTGTTGCTGTA-3’ were used to provide
a normalization control. Multiplex PCR was performed with the
following parameters: 94˚C for 5 min; 22 cycles at 94˚C for 30 s,
65˚C for 30 s and 72˚C for 2 min. PCR products were visualized
with ethidium bromide following agarose gel electrophoresis
(Sambrook et al, 1989).
DNA sequencing
All DNA sequencing was performed using an automated ABI 377
DNA sequencing system and a standard dye terminator AmpliTaq
kit (Perkin Elmer, Buckinghamshire, UK). The resulting sequences
were analysed for homology in the public GenBank/EMBL/DDBJ/
PDB and Expressed Sequence Tag (EST) databases using the
basic local alignment search tool (BLAST) program (http://
www.ncbi.nlm.nih.gov/BLAST) (Altschul et al, 1990).
RESULTS
A subtracted library was constructed which contained cloned
cDNAs representing mRNAs present at a higher level in a cell line
(Huma 123) derived from benign breast disease than in the malig-
nant breast tumour-derived cell line, MCF-7A and screened by
nucleotide sequencing of 128 randomly-picked clones (approxi-
mately 10% of the library). Figure 1 shows the pattern of reverse
Northern hybridization of a panel of just 12 of these cDNAs from
the library including the cDNA for ribosomal protein L6, an abun-
dant mRNA which is not differentially expressed to a large extent.
The PCR-based suppression subtraction procedure yields some
differentially expressed cloned cDNAs that are not easily detected
in the reverse Northern screen (clones 3–7, 11, 12, Figure 1) and
more-abundant cDNAs (clones 1, 2, 8 and 10) which are easily
detected. Amongst these easily-detected cDNAs were those for
plasminogen activator inhibitor I (11.6-fold elevated in the Huma
123 cells), annexin VIII (10.5-fold) and S100A2. This latter cDNA
(number 1 in Figure 1), exhibited 100% identity to the sequence of
human S100A2, a member of the S100 family of EF-hand proteins
(Donato, 1999). Quantitation of the reverse Northern hybridization
experiments using as probes single-stranded cDNAs from the
Huma 123 or the MCF-7A cells confirmed that the level of
S100A2 mRNA was at least 20-fold higher in the RNA from
Huma 123 cells than in RNA from the MCF-7A cells (Figure 1),
and that this degree of difference is greater than for some other
differentially expressed mRNAs (Figure 1D), for example that of
plasminogen activator inhibitor (11.6-fold).
S100A2 has been previously reported to be present in normal
mammary epithelial tissue, but to be absent in breast cancer
derived cells (Lee et al, 1992). Its abundance in a library from
benign breast disease subtracted with RNA from the more malig-
nant MCF-7A cells suggests that S100A2 mRNA might also be
present in benign tumour-derived cells. A DNA probe corre-
sponding to the S100A2 cDNA isolated from the subtracted library
hybridized to a single highly abundant mRNA of 0.45 kb in Huma
123 RNA, confirming the expression of S100A2 mRNA in this
cell line (Figure 2). Two additional faint hybridization bands at
4 kb and 2.5 kb in this lane (signified by arrows in Figure 2) prob-
ably correspond to unprocessed mRNA, one band containing both
of the two introns (intron 1 of 1623 bp and intron 2 of 1961 bp) of
the human S100A2 gene, and the other containing only intron 2
(Wicki et al, 1997). The Northern blotting experiments also show
that the mRNA for S100A2 is present in a myoepithelial-like elon-
gated convert, Huma 109, derived from the cell line Huma 123 and
in an SV40-virus-immortalized cell line, Huma 7, derived from
normal human mammary gland, but at a lower level relative to a
constitutive mRNA than in the Huma 123 line (Figure 2). S100A2
mRNA is undetectable in RNA from malignant breast cancer cell
lines, MCF-7A, T-47D, ZR-75 and MDA-MB-231 using standard
Northern blotting procedures (Figure 2).
In order to examine the occurrence of S100A2 mRNA in tumour
specimens, RT-PCR was used to amplify S100A2 mRNA specifi-
cally from RNA prepared from benign lesions and malignant
human breast carcinoma specimens. Control amplifications of
S100A2 in breast tumour specimens 1475
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S100A2 mRNA was amplified from RNA from cell lines derived
from normal and benign human mammary epithelium, but not
from cell lines derived from breast carcinomas when 22 cycles of
PCR were used. When PCR was carried out using this same
number of cycles, amplification of S100A2 mRNA was evident in
RNA from specimens of benign disease, but not from specimens
of breast carcinomas (Figure 3).
In order to identify whether the S100A2 mRNA arose from nor-
mal or abnormal epithelium within the benign disease specimens,
histological sections of benign specimens were subjected to in situ
hybridization, using sense and antisense RNA probes specific
for S100A2 mRNA. Antisense probes hybridized strongly to the
ductal and lobular epithelial components, but not to the stromal
components on sections of normal human breast, whereas sense
probes failed to hybridize, even though tissue was present in the
same field (Figure 4). The absence of a signal with the sense
probe, and the fact that the antisense probe failed to stain the
nuclei of the cells indicates that there was no hybridization of the
probe to genomic DNA (Figure 4).
When histological sections from a panel of 27 carcinoma
specimens were examined by in situ hybridization, there was
no staining of the majority (23/27) of the specimens (Figure 4; 
Table 2), however, there was weak staining in 4 carcinoma speci-
mens (Table 2). Of the 4 carcinoma specimens which contained low
levels of S100A2 mRNA, 2 were estrogen receptor positive and
1476 D Liu et al
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Huma 123
MCF-7A
Clone No. Blast search Accession No.
 1 Human S100A2 mRNA M87068
 2 Human PAI-1 mRNA X04744
 3 Human mRNA for ets-2 J04102
 4 Human SHC mRNA X68148
 5 Human protocadherin Fat 2 mRNA AF231022
 6 Human TNFR2-TRAF mRNA L49432
 7 Human XIST mRNA M97168
 8 Human anexin VIII mRNA M81844
 9 Human  mRNA for ribosomal protein L6 M69391
10 Human  mRNA for p cadherin M63629
11 Unknown gene AF257108
12 Human MEN1 region mRNA AF001893
Figure 1 Reverse Northern hybridization of clones selected randomly from
a cDNA library from a benign mammary derived cell line, Huma 123,
suppression subtracted with driver cDNA derived from MCF-7A cells. 11
randomly-picked cloned cDNAs from the Huma 123 library were amplified by
PCR, spotted onto duplicate Nylon filters and each filter hybridized separately
with mixed cDNA probes of equal specific activity derived from Huma 123
RNA (Panel A) or MCF-7A RNA (Panel B), as described in Materials and
Methods. The intensities of the autoradiographic images in (A) and (B) were
quantified as described in Materials and Methods (Panel C). The cDNA for
ribosomal protein L6 is included as a control for a cDNA which shows similar
expression in the Huma 123 and MCF-7A cell lines. Panel D tabulates the
identities of the cloned cDNAs 1–12 (Panels A–C) from their nucleotide
sequence data. Clone 11 has been submitted to the GenBank database
(Accession number AF257108). Human PAI-1 is Human plasminogen
activator inhibitor 1 (Wun and Kretzmer, 1987); human ets-2 is human
erythroblastosis virus oncogene homologue 2 mRNA (Watson et al, 1988);
human SHC is the Src homology 2 (SH2) domain-containing transforming
protein (Pelicci et al, 1992); human TNFR2-TRAF is the tumour necrosis
factor receptor 2 (TNFR2)–TNF receptor associated factors (TRAF) signalling
complex protein (Rothe et al, 1995); human XIST is human X (inactive)-
specific transcript (Willard et al, 1992); human MEN1 is Multiple endocrine
neoplasia type 1 protein (Guru et al, 1997)
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Figure 2 Northern hybridization of S100A2 mRNA from human mammary
cell lines derived from benign and malignant breast tumours. 10 µ g of RNA
from each of the SV40-immortalized human mammary cell line, Huma 7
(lane 1), the benign mammary derived cell line Huma 123 (lane 3), an
elongated converted cell line, Huma 109 (lane 2), derived from Huma 123,
the malignant mammary epithelial cell lines MCF-7A (lane 4), T-47D (lane 5),
ZR-75 (lane 6) and MDA-MB-231 (lane 7) were subjected to Northern blotting
and hybridization as described in Materials and Methods using 32P-labelled
probes to S100A2 mRNA (Panel A) or to ribosomal phosphoprotein, 36B4
(Panel B) for normalization purposes. The arrows point to faint bands of
hybridization in the Huma 123 RNA
kb
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Figure 3 The occurrence of S1002 mRNA in RNA from benign and
malignant human mammary cell lines and breast tumour specimens by 
RT-PCR. RNA from normal and benign human mammary cell lines, Huma 7
(lane 1), Huma 123 (lane 2), Huma 109 (lane 3), and breast carcinoma-
derived cell lines, MCF-7A (lane 4), T-47D (lane 5), ZR-75 (lane 6), MDA-MB-
231 (lane 7), benign breast specimens (lanes 8–13) and breast carcinoma
specimens (lanes 14–18) was amplified by RT-PCR using primers specific for
S100A2 (S100A2) and human glyceraldehyde-3-phosphate dehydrogenase
(GPDH) mRNA to yield PCR products of 258 bp and 452 bp, respectively.
The resulting RT-PCR products were subjected to agarose gel
electrophoresis and stained with ethidium bromide, as described in Materials
and Methods. Lane M, DNA molecular weight markersnode negative, one was estrogen receptor positive and of unknown
nodal status, and one was estrogen receptor positive node positive.
When benign breast tumour and hyperplastic specimens were
subjected to in situ hybridization, the epithelial cells surrounding
the abnormal ductal structures stained strongly for S100A2 mRNA
in all 15 specimens (Figure 5, Table 2), although a comparison
of the staining of normal and benign structures on the same 
sections suggested that in some sections the benign specimens
stained slightly less strongly than the normal ductal structures
(not shown).
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Figure 4 In situ hybridization of S100A2 mRNA in normal human mammary gland and in a human breast carcinoma. Histological sections of normal mammary
gland (Panels A and B) and a carcinoma specimen (panel C) were subjected to in situ hybridization using anti-sense (Panels A and C) or sense (Panel B)
probes to S100A2 mRNA as described in Materials and Methods. An adjacent histological section from the carcinoma specimen was stained with haematoxylin
and eosin (Panel D). Magnification is × 206; bars = 50 µ m.
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CD
EF
Figure 5 In situ hybridization of S100A2 mRNA in benign human breast lesions and in ductal carcinomas in situ. Histological sections of benign tumours, of
fibroadenoma (Panels A, B), of hyperplasia (Panels C, D), or of an S100A2-positive (Panel E) and an S100A2-negative (Panel F) ductal carcinoma in situ were
subjected to in situ hybridization with anti-sense (Panels A and C–F) or sense (Panel B) probes as described in Materials and Methods. Magnification is × 206
(Panels A–D) or × 165 (Panels E and F). Bars = 50 µ m (Panels A–D) or 60 µ m (Panels E and F).In contrast to the benign tumour and hyperplastic specimens, the
staining of carcinoma in situ was much more variable (Figure 5,
Table 2). Only 7/19 (37%) of the specimens of carcinoma in
situ examined stained positively for S100A2 mRNA, whilst
the remaining 12 specimens exhibited a complete absence of
S100A2 mRNA (Figure 5; Table 2). Those specimens which
stained positively showed a patchy staining which was generally
less intense than the staining of either normal or benign epithelial
cells (Figure 5E).
DISCUSSION
Amongst cDNAs expressed at a markedly higher level in the
benign human mammary cell line, Huma 123, than in the malig-
nant MCF-7 cells were annexin VIII, plasminogen activator
inhibitor-1 and S100A2. This is the first report of down-regulation
of annexin VIII in human malignant breast cells, however, annexin
VIII has previously been identified as being up-regulated in acute
promyelocytic leukaemias (APL) but not in other leukaemic cells.
This up-regulation is thought to be a result of the down-regulation
of the retinoic acid receptor in promyelocytic leukaemia (Chang et
al, 1992). Thus, in the mammary cells, the differential expression
of annexin VIII might also reflect changes in the function of the
retinoic acid receptor.
S100A2 mRNA has been found to be expressed abundantly in
benign human breast cell lines and, as reported previously (Lee et
al, 1992), to be undetectable by Northern blotting in cell lines
derived from breast carcinoma cell lines, MCF-7A, ZR-75, T-47D.
The cell line MDA-MB-231 was similarly negative, however, this
latter cell line has been previously shown to contain S100A2
mRNA (Pedrocchi et al, 1994) and protein, which has been
reported to be located in the nucleus in these cells (Mueller et al,
1999). In the present experiments, a faint band of hybridization
was detectable in RNA from the MDA-MB-231 cells when
Northern blots were highly overexposed suggesting the presence
of low levels of S100A2 mRNA in these particular cells.
Using in situ hybridization, S100A2 mRNA has been shown to
be present in normal human breast epithelium and to be generally
absent in breast carcinoma specimens, as expected. However,
unexpectedly, there was a very low level of staining for S100A2
mRNA in a small proportion (4/27) of breast carcinoma speci-
mens, a result that is entirely consistent with the detection of low
levels of S100A2 mRNA in one of 4 malignant breast carcinoma
cell lines.
It has previously been suggested that S100A2 is up-regulated
upon stimulation of p53-dependent apoptosis (Wang et al, 1999),
and in transactivation assays it has been shown that the S100A2
promoter can be transcriptionally activated by wild-type, but not
by mutant, p53 (Tan et al, 1999). In the present group of speci-
mens, it seems unlikely that the down-regulation of S100A2 arises
from the presence of mutant, and therefore inactive, p53 as indi-
cated by the presence of nuclear staining for p53, since 8 S100A2-
negative specimens were also negative for p53, suggesting a
normal p53 phenotype in these specimens. Apart from the possi-
bility that these carcinoma specimens exhibited a p53 null pheno-
type due to deletion of both copies of the p53 gene, it is likely that
the loss of S100A2 in the majority of carcinoma cells is due to
other mechanisms, such as methylation of the S100A2 gene (Lee
et al, 1992; Wicki et al, 1997).
The present experiments are the first report of S100A2 mRNA
occurring in benign breast specimens both in benign tumours and
in hyperplastic lesions. Not only was S100A2 mRNA present in
100% of 15 benign tumour and hyperplastic lesions examined, but
also the staining was hardly less than that in the normal mammary
parenchyma. This is the first report of the presence of S100A2 in
benign breast neoplastic or hyperplastic cells, although S100A2
mRNA has been shown previously to occur in benign naevi of the
skin (Maelandsmo et al, 1997). Since S100A2 mRNA is almost
completely absent in the breast carcinoma cells examined, the
results of the present experiments suggest that S100A2 mRNA
becomes down-regulated during the formation of carcinoma cells,
at least in the breast, and not at the earlier stage of the development
of benign hyperplastic and neoplastic cells from normal epithe-
lium. These results suggest that S100A2 is not a simple suppressor
of tumour cell growth (Lee et al, 1992), but it might be the result of
tumour progression or otherwise associated with it.
Furthermore, S100A2 mRNA is present in the carcinoma cells
in only 37% of carcinoma in situ examined and that, in these
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Table 2 Staining of tumour specimens for S100A2 mRNA by in situ hybridization
Tissue specimen In situ hybridization for S100A2 mRNA
Total number of Number of S100A2 Number of S100A2
specimens positive specimens negative specimens
Normal gland 3 3 0
Normal region of tumour specimens 5 5 0
Benign lesions 15 15 0
Carcinoma in situa 19 7 12
p53 positive 8 2 6
p53 negativeb 94 5
Unknown p53 2 1 1
Carcinomac 27 4 23
p53 positive 12 0 12
p53 negatived 11 3 8
Unknown p53 4 1 3
aSignificantly different from normal (P = 0.0096) or benign (P = 0.005) specimens (Fisher Exact Test). Not significantly different from
carcinoma specimens (P >0.16; Fisher Exact Test). bNot significantly different from p53-positive carcinoma in situ specimens (P = 0.742;
Fisher Exact Test). cSignificantly different from normal (P < 0.0001) or benign (P = 0.0001) specimens (Fisher Exact Test). Not significantly
different from carcinoma in situ specimens (P > 0.16; Fisher Exact Test). dNot significantly different from p53-positive carcinoma in situ
specimens (P = 0.187; Fisher Exact Test).S100A2 in breast tumour specimens 1479
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specimens, the proportion of cells staining is considerably reduced
relative to the benign lesions. Since S100A2, uniquely amongst the
S100A proteins, has been suggested to have a nuclear localization
in some cells, for example, human vascular smooth muscle cells
(Mandinova et al, 1998), and in the Huma 7 breast epithelial cells
(Elenis and Wang, personal communication), one of the cell lines
used in the present study, it is possible that the loss of S100A2 is
associated with changes in the nucleus which reflect the progres-
sion to the malignant phenotype in human breast carcinomas.
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